Brincidofovir mortality rate holds up in Chimerix's adenovirus study

The latest results from Chimerix's ongoing clinical trial for brincidofovir in the treatment of adenovirus in immunocompromised patients show that trial's mortality rate is holding steady as the study transitions to the pivotal Phase III trial.